Alnylam Pharmaceuticals, Inc Aktie News

The UK's drug cost-effectiveness watchdog has recommended Alnylam Pharmaceuticals' heart disease drug, ensuring access for patients through the government health system in England and Wales, the company said on Friday.

Alnylam stock is holding its 50-day moving average as it seeks to get back to its buy point of 484.21.

Alnylam Pharmaceuticals, Inc. ( ALNY ) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Yvonne Greenstreet - CEO & Director Tolga Tanguler - Executive VP & Chief Commercial Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is M...

Alnylam Pharmaceuticals boasts an exciting product lineup and pipeline. IonQ could be one of the biggest winners in the fast-growing quantum computing market.

Alnylam Pharmaceuticals, Inc. ( ALNY ) UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Company Participants Jeffrey Poulton - CFO & Executive VP John Vest - Senior Vice President of Clinical Research Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, every...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy of he...

Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Alnylam's shares benefited from a positive phase 3 trial by Regeneron Pharmaceuticals that uses Alnylam's technology. We initiated a position in AppLovin, the only scaled, global advertisement network for gaming properties.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: UBS Global Healthcare Conference on Monday, November 10, 2025, at 10:15 AM ET in Palm Beach Gardens, Florida Jefferies Global Healthcare Conference on Wednesday, Nove...